SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008, beginning at 12:00 p.m. Eastern Time. The webcast portion of this event will conclude at approximately 3:30 p.m.
Nektar's R&D Day will consist of a series of presentations and Q&A related to the Company's clinical development programs, key research and development, and industry-leading PEGylation and conjugate chemistry-based drug development platform.
The presentations and Q&A sessions will be accessible via a live audio and slideshow webcast through a link on the Nektar homepage, http://www.nektar.com. The webcast will be available for replay until November 26, 2008.
Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its PEGylation and conjugate chemistry technology
platforms. Nektar's technology and drug development expertise have enabled
nine approved products for partners, which include leading
biopharmaceutical companies. Nektar is also developing a robust pipeline of
its own high-value therapeutics that addresses unmet medical needs by
leveraging and expanding its technology platforms to improve and enable
Stephan Herrera, 415-488-7699
Jennifer Ruddock, 650-631-4954
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved